Veronika Felicitas Klose

Dr. Veronika Felicitas Klose

University of Ulm, Ulm, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in European Journal of Neurology
Verified
Journal Article
Open access
KXKailin Xia
Kailin Xia
VKVeronika Felicitas Klose
Veronika Felicitas Klose
JHJosef Högel
Josef Högel
THTao Huang
Tao Huang
LZLinjing Zhang
Linjing Zhang
ALAlbert C. Ludolph
Albert C. Ludolph
Objective: Previous observational studies revealed a potential but partially controversial relation between lipid metabolism and the risk of amyotrophic lateral sclerosis (ALS), potentially prone to bias. Therefore, we aimed to study whether lipid metabolism involves genetically determined risk factors for ALS through Mendelian randomization (MR) analysis.Methods: Using genome‐wide association study summary‐level data for total cholesterol (TC) (n = 188,578), high‐density lipoprotein cholesterol (HDL‐C) (n = 403,943), low‐density lipoprotein cholesterol (LDL‐C) (n = 440,546), apolipoprotein A1 (ApoA1) (n = 391,193), apolipoprotein B (ApoB) (n = 439,214), and ALS (12,577 cases and 23,475 controls), we implemented a bidirectional MR study to evaluate a genetic relation between lipids and ALS risk. We performed a mediation analysis to assess whether LDL‐C is a potential mediator on the pathway from traits of LDL‐C‐related polyunsaturated fatty acids (PUFAs) to ALS risk.Results: We identified genetically predicted increased lipid levels to be associated with the risk of ALS, whereby elevated LDL‐C had the most potent effect (OR 1.028, 95% CI 1.008–1.049, p = 0.006). The effect of increased levels of apolipoproteins on ALS was similar to their corresponding lipoproteins. ALS did not cause any changes in lipid levels. We found no relation between LDL‐C‐modifying lifestyles and ALS. The mediation analysis revealed that LDL‐C could act as an active mediator for linoleic acid, with the mediation effect estimated to be 0.009.Conclusions: We provided high‐level genetic evidence verifying the positive link between preclinically elevated lipid and ALS risk that had been described in previous genetic and observational studies. We also demonstrated the mediating role of LDL‐C in the pathway from PUFAs to ALS.

17 October 2022 in European Journal of Neurology
Verified
Journal Article
Open access
KXKailin Xia
Kailin Xia
SWSimon Witzel
Simon Witzel
CWChristina Witzel
Christina Witzel
VKVeronika Felicitas Klose
Veronika Felicitas Klose
DFDongsheng Fan
Dongsheng Fan
JDJohannes Dorst
Johannes Dorst
Background and purpose: Growing evidence shows that ALS patients feature a disturbed energy metabolism. However, these features have rarely been investigated in the presymptomatic stage.Methods: A total of 60 presymptomatic ALS mutation carriers and 70 age‐ and gender‐matched controls (non‐mutation carriers from the same families) were recruited. All subjects underwent assessments of their metabolic profiles under fasting conditions at enrollment, including body mass index (BMI), blood pressure and serum levels of blood glucose, total cholesterol, triglycerides, high‐density lipoprotein (HDL) and low‐density lipoprotein.Results: All mutations combined, no differences between presymptomatic ALS gene carriers and controls were found. From a cardiovascular point of view, presymptomatic chromosome 9 open reading frame 72 (C9ORF72) gene carriers showed lower cardiovascular risk profiles compared to healthy controls, including lower BMI (median 22.9, interquartile range [IQR] 20.6–26.1 kg/m2 vs. 24.9, IQR 22.7–30.5 kg/m2; p = 0.007), lower systolic blood pressure (120, IQR 110–130 mmHg vs. 128, IQR 120–140 mmHg; p = 0.02), lower fasting serum glucose (89.0, IQR 85.0–97.0 mg/dl vs. 96.0, IQR 89.3–102.0 mg/dl; p = 0.005) and higher HDL (1.6, IQR 1.3–1.8 mmol/l vs. 1.2, IQR 1.0–1.4 mmol/l; p = 0.04). However, presymptomatic superoxide dismutase 1 (SOD1) gene mutation carriers showed higher cardiovascular risk profiles compared to healthy controls, including higher BMI (28.0, IQR 26.1–31.5 kg/m2 vs. 24.9, IQR 22.7–30.5 kg/m2; p = 0.02), higher fasting serum glucose (100.0, IQR 94.0–117.0 mg/dl vs. 96.0, IQR 89.3–102.0 mg/dl; p = 0.04) and lower HDL (1.2, IQR 1.0–1.4 mmol/l vs. 1.4, IQR 1.2–1.7 mmol/l; p = 0.01). These features were most prominent in patients carrying SOD1 gene mutations associated with slow disease progression.Conclusions: This study identified distinct metabolic profiles in presymptomatic ALS gene carriers, which might be associated with disease progression in the symptomatic phase.

Verified
Journal Article
Open access
PDF file
DEDeborah Katharina Erhart
Deborah Katharina Erhart
VKVeronika Felicitas Klose
Veronika Felicitas Klose
TSTatjana Schäper
Tatjana Schäper
Hayrettin TumaniHayrettin Tumani
Hayrettin Tumani
MSMakbule Senel
Makbule Senel
C-X-C-motif chemokine ligand 13 (CXCL13) in cerebrospinal fluid (CSF) is increasingly used in clinical routines, although its diagnostic specificity and divergent cut-off values have been defined so far mainly for neuroborreliosis. Our aim was to evaluate the value of CSF-CXCL13 as a diagnostic and treatment response marker and its role as an activity marker in a larger disease spectrum, including neuroborreliosis and other neuroinflammatory and malignant CNS-disorders. Patients who received a diagnostic lumbar puncture (LP) (n = 1234) between July 2009 and January 2023 were included in our retrospective cross-sectional study. The diagnostic performance of CSF-CXCL13 for acute neuroborreliosis was highest at a cut-off of 428.92 pg/mL (sensitivity: 92.1%; specificity: 96.5%). In addition, CXCL13 levels in CSF were significantly elevated in multiple sclerosis with clinical (p = 0.001) and radiographic disease activity (p < 0.001). The clinical utility of CSF-CXCL13 appears to be multifaceted. CSF-CXCL13 is significantly elevated in patients with neuroborreliosis and shows a rapid and sharp decline with antibiotic therapy, but it is not specific for this disease and is also highly elevated in less common subacute neuroinfectious diseases, such as neurosyphilis and cryptococcal meningitis or in primary/secondary B-cell lymphoma.

14 May 2024 in Brain
Verified
Journal Article
Closed access
PDF file
VKVeronika Felicitas Klose
Veronika Felicitas Klose
SJSarah Jesse
Sarah Jesse
JLJan Lewerenz
Jan Lewerenz
JKJan Kassubek
Jan Kassubek
JDJohannes Dorst
Johannes Dorst
ALA. C. Ludolph
A. C. Ludolph
The integrity of the blood–CSF barrier plays a major role in inflammation, but also in shielding the CNS from external and systemic—potentially toxic—factors. Here we report results of measurements of the albumin quotient—which is thought to mirror the integrity of the blood-CSF barrier—in 1059 patients with amyotrophic lateral sclerosis. The results were compared with groups of patients suffering from Alzheimer’s disease, facial palsy and tension headache. The albumin quotient, an accepted measure of the blood-CSF barrier integrity, was not significantly different from control populations. In addition, we found that the albumin quotient correlated with survival of the patients; this effect was mainly driven by male patients and influenced by age, body mass index and diabetes mellitus. We conclude that the blood-CSF barrier is intact in this large cohort of patients with amyotrophic lateral sclerosis and that the albumin quotient correlates with survival. Whether this is important for the pathogenesis of the disease, requires mechanistic studies.

13 October 2025 in Clinical Chemistry
Verified
Journal Article
Open access
SHSteffen Halbgebauer
Steffen Halbgebauer
BFBadrieh Fazeli
Badrieh Fazeli
VKVeronika Felicitas Klose
Veronika Felicitas Klose
GNGabriele Nagel
Gabriele Nagel
ARAngela Rosenbohm
Angela Rosenbohm
HTHayrettin Tumani
Hayrettin Tumani
Background: Serum glial fibrillary acidic protein (GFAP) is a biomarker for astrocytic injury and astrogliosis. Concentrations are elevated in numerous neurological disorders, including a pronounced increase in Alzheimer disease (AD). However, GFAP levels in the serum also increase with age. Consequently, the integration of GFAP levels into clinical routine and their interpretation demands age-adjusted reference values. Methods: Serum from 1273 subjects (952 noninflammatory and nonneurodegenerative neurological controls and 321 subjects with AD) was analyzed for GFAP using the microfluidic Ella system. Age-dependent serum GFAP reference values were estimated by additive quantile regression analysis and visualized with percentiles and z-scores. Results: AD exhibited elevated serum GFAP levels in comparison to control patients (P < 0.0001). This remained the case when the newly generated age-corrected z-scores were applied (P < 0.0001). In the control cohort, a nonlinear elevation of serum GFAP with increasing age was observed (Spearman correlation coefficient 0.62, 95% CI 0.58–0.66, P < 0.0001). In contrast, the AD cohort exhibited a more linear increase (0.16, 95% CI 0.05–0.26, P = 0.004). Age-dependent cut-offs for serum GFAP were determined for different AD age groups. The calculated areas under the curve (AUCs; 0.97) demonstrated excellent diagnostic test performance in the early-onset age group. This effect was less marked in the elderly subjects (AUC 0.72). Conclusions: Our novel GFAP z-scores enable the integration and interpretation of serum GFAP levels in clinical practice, moving from the group to individual level. They support both intra- and interindividual interpretation of single GFAP levels in neurological diseases with astrocytic pathology, including an accurate discrimination of AD.

5 May 2023 in Frontiers in Neurology
Verified
Journal Article
Open access
VKVeronika Felicitas Klose
Veronika Felicitas Klose
SJSarah Jesse
Sarah Jesse
JLJan Lewerenz
Jan Lewerenz
JKJan Kassubek
Jan Kassubek
JDJohannes Dorst
Johannes Dorst
FRFrancesco Roselli
Francesco Roselli
Introduction: Amyotrophic Lateral Sclerosis (ALS) is characterized by progressive motoneuron degeneration through cell autonomous and non-cell autonomous mechanisms; and the involvement of the innate and adaptive immune system has been hypothesized based on human and murine model data. We have explored if B-cell activation and IgG responses, as detected by IgG Oligoclonal bands (OCB) in serum and cerebrospinal fluid, were associated with ALS or with a subgroup of patients with distinct clinical features.Methods: IgG OCB were determined in patients affected by ALS (n=457), Alzheimer Disease (n=516), Mild Cognitive Impairment (n=91), Tension-type Headache (n=152) and idiopathic Facial Palsy (n=94). For ALS patients, clinico-demographic and survival data were prospectively collected in the Register Schabia.Results: The prevalence of IgG OCB is comparable in ALS and the four neurological cohorts. When the OCB pattern was considered (highlighting either intrathecal or systemic B-cells activation), no effect of OCB pattern on clinic-demographic parameters and overall. ALS patients with intrathecal IgG synthesis (type 2 and 3) were more likely to display infectious, inflammatory or systemic autoimmune conditions.Discussion: These data suggest that OCB are not related to ALS pathophysiology but rather are a finding possibly indicative a coincidental infectious or inflammatory comorbidity that merits further investigation.